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Abstract Somatic mutations in the isocitrate dehydroge-
nase 1 gene (IDH1) occur at high frequency in gliomas and
seem to be a prognostic factor for survival in glioblastoma
patients. In our set of 98 glioblastoma patients, IDH1
R132
mutations were associated with improved survival of 1 year
on average, after correcting for age and other variables with
Cox proportional hazards models. Patients with IDH1
mutations were on average 17 years younger than patients
without mutation. Mutated IDH1 has a gain of function to
produce 2-hydroxyglutarate by NADPH-dependent reduc-
tion of a-ketoglutarate, but it is unknown whether NADPH
production in gliomas is affected by IDH1 mutations. We
assessed the effect of IDH1
R132 mutations on IDH-mediated
NADPH production in glioblastomas in situ. Metabolic
mapping and image analysis was applied to 51 glioblastoma
samples of which 16 carried an IDH1
R132 mutation.
NADP
?-dependent IDH activity was determined in com-
parison with activity of NAD
?-dependent IDH and all other
NADPH-producing dehydrogenases, glucose-6-phosphate
dehydrogenase,6-phosphogluconatedehydrogenase,malate
dehydrogenase, and hexose-6-phosphate dehydrogenase.
The occurrence of IDH1 mutations correlated with approx.
twofold diminished NADP
?-dependent IDH activity,
whereas activity of NAD
?-dependent IDH and the other
NADP
?-dependent dehydrogenases was not affected in situ
in glioblastoma. The total NADPH production capacity in
glioblastoma was provided for 65% by IDH activity and the
occurrence of IDH1
R132 mutation reduced this capacity by
38%.ItisconcludedthatNADPHproductionishamperedin
glioblastoma with IDH1
R132 mutation. Moreover, mutated
IDH1 consumes rather than produces NADPH, thus likely
lowering NADPH levels even further. The low NADPH
levels may sensitize glioblastoma to irradiation and che-
motherapy, thus explaining the prolonged survival of
patients with mutated glioblastoma.
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Introduction
Primary and secondary glioblastomas display somatic
mutations in the IDH1 gene. The mutation is relatively rare
in primary glioblastoma (approx. 5% of the tumors harbor
the mutation) and frequent in secondary glioblastoma (70–
80% of the tumors carry the mutation [3, 5, 10, 12, 19, 21,
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?-dependent
isocitrate dehydrogenase 1, which can be found in cyto-
plasm, peroxisomes [9] and endoplasmic reticulum [18]
and belongs to a gene family encompassing ﬁve members
[9, 18]. Wild-type IDH1 catalyzes the oxidative decar-
boxylation of isocitrate to a-ketoglutarate [15] with
concomitant production of NADPH. Mutations in IDH1 are
tumor speciﬁc and have so far been detected in various
types of gliomas, especially in those histologically classi-
ﬁed as low-grade gliomas and secondary glioblastoma [3,
5, 10, 12, 19, 21, 24, 32, 33, 36] and in a subset of acute
myeloid leukemia [17]. Mutations affecting the isocitrate
dehydrogenase 2 gene (IDH2), another NADP
?-dependent
IDH localized in mitochondria, have also been described in
gliomas although at lower frequency [10, 25, 36]. The other
three members of the IDH family are exclusively localized
in mitochondria, depend on NAD
? for their enzymatic
activity and play a relevant role in the Krebs cycle [37].
These NAD
?-dependent IDHs are not known to be mutated
in relation to gliomagenesis.
The mutational proﬁle of IDH1 and IDH2 is peculiar as
the mutations affect only single evolutionarily conserved
residues (arginines R132 and R172, respectively). The
arginines are localized in the substrate binding site of
the isozymes, where hydrophilic interactions between the
arginine and both a- and b-carboxylate of isocitrate
are formed [35]. Interestingly, from a genetic perspective
the pattern of IDH1 mutations is consistent with a gain of
function (such as those occurring in oncogenes). However,
it has been shown that the mutations inactivate the standard
enzymatic activity of IDH1 and IDH2 [12, 36]. As a con-
sequence, a-ketoglutarate levels are reduced when IDH1 is
mutated. a-Ketoglutarate in the cytoplasm initiates oxygen-
dependent degradation of hypoxia-inducible factor subunit
HIF-1a [22, 27, 38]. Thus, decreased cytoplasmic levels of
a-ketoglutarate increase levels of HIF-1a and the hetero-
dimer HIF-1 consisting of HIF-1a and HIF-1b is
transported into the nucleus for transcriptional activity [11,
22, 27]. HIF-1 is the master switch of cellular adaptation to
low oxygen tension and induces transcription of genes
involved in angiogenesis, cell motility and invasion and
energy metabolism [11]. Furthermore, a recent report has
shown that mutated IDH1 does not convert isocitrate and
NADP
? into a-ketoglutarate and NADPH but rather has a
gain of function enabling IDH1 to convert a-ketoglutarate
and NADPH into 2-hydroxyglutarate and NADP
? [8]. It
was shown that glioma samples with the IDH1 mutation
contained high 2-hydroxyglutarate levels [8]. Interestingly,
in patients with 2-hydroxyglutarate dehydrogenase deﬁ-
ciency, 2-hydroxyglutarate accumulation is associated with
a higher risk of malignant brain tumors [1].
How the IDH1
R132 mutations affect NADPH production
in human tumors is presently unknown and is a matter of
debate [22, 27]. NADPH plays an important role in
detoxiﬁcation processes and scavenging of oxygen radicals
[14] and thus is a protective compound in cancer cells
under stress during irradiation or chemotherapy.
In the present study, we correlated the occurrence of
IDH1
R132 mutations with overall survival of glioblastoma
patients using multivariable analysis. Furthermore, we
applied metabolic mapping and image analysis to assess
the NADP
?-dependent and NAD
?-dependent enzymatic
activity of IDH in comparison with the activity of all other
NADPH-producing dehydrogenases [30] in glioblastoma in
situ. This strategy was then exploited to correlate the IDH1
mutational status with its enzymatic activity.
Materials and methods
Tumor samples, isolation of DNA, PCR, sequencing
and mutation analysis
DNA samples of 109 frozen glioblastomas, for which the
mutational status of IDH1 was previously determined [5],
were obtained from the tumor bank maintained by the
Departments of Neurosurgery and Neuropathology at the
Academic Medical Center (Amsterdam, The Netherlands).
In the present study, these glioblastoma samples were
analyzed for IDH2 mutations, and a subset of these samples
was used for survival analysis and enzyme activity. Use of
material was waived by our local ethics committee, as it
fell under the Dutch Code of proper secondary use of
human tissue. The research was performed on ‘waste’
material, stored in a coded fashion.
Tumor samples were included only if at least 80% of the
sample consisted of cancer cells, as veriﬁed by H&E
staining. Genomic DNA was isolated as previously
described [2]. PCR, sequencing and mutation analysis
details have been described previously [5].
Glioblastoma patient data
A retrospective survival analysis was performed for 98
glioblastoma patients with known follow-up. Both primary
(85) and secondary glioblastoma (13), but no recurrent
glioblastoma patients were included. These patients
underwent brain surgery at the AMC between 1988 and
2006 and were selected, when enough tissue was available
to perform the experiments described. Patient characteris-
tics are displayed in Table 1. The primary end point of this
analysis was overall survival, calculated as time from
surgery to death. Events were censored if the patient was
alive at the time of last follow-up. Follow-up for patients
ranged from 15 to 2,722 days. The median overall survival
was 262 days; the 2-year survival rate was 15%. Patients
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123have been treated with different regimens either in trials or
with standard protocols. Other therapies in addition to
irradiation included chemoradiation (radiotherapy with
concomitant and adjuvant temodal), brachytherapy, gliadel,
PCV, temodal, MTX and nicotinamine (an enhancer during
irradiation).
Metabolic mapping
Glioblastoma and normal brain tissue were snap-frozen in
liquid nitrogen in the operating room, and stored at -80C
until used. Normal brain sections contained both grey and
white matter. Six-lm-thick cryostat sections were cut at
-25C on a HM560 cryostat (MICROM, Walldorf, Ger-
many), picked up on glass slides, and stored at -80C until
used [30]. Cryostat sections of glioblastoma tissue were
allowed to dry at room temperature for 5 min and were
then incubated for the demonstration of IDH, G6PDH,
6PGDH, MDH and H6PDH activity [26, 29]. Incubation
media contained 18% polyvinyl alcohol (PVA, average
molecular mass 70,000–100,000; Sigma, St. Louis, MO) in
0.1 M phosphate buffer, pH 7.4, 0.32 mM 1-methoxy-
phenazine methosulfate (Serva, Heidelberg, Germany),
5 mM sodium azide, 5 mM MgCl2, 5 mM nitro BT
(Sigma), and either 20 mM D,L-isocitrate (Sigma) or
10 mM glucose-6-phosphate (Serva), or 10 mM 6-phos-
phogluconate (Sigma), or 100 mM malate (Serva), or
10 mM galactose-6-phosphate (Sigma) to demonstrate
activity of IDH, G6PDH, 6PGDH, MDH, or H6PDH,
respectively. For NADP
?-dependent dehydrogenases,
0.8 mM NADP
? (Roche, Mannheim, Germany) was used
as co-enzyme, whereas for the NAD
?-dependent IDH
activity, 4 mM NAD
? (Roche) was used. The concentra-
tions of the substrates and co-enzymes in the incubation
media were sufﬁciently high to ensure maximum velocity
(Vmax) of the enzyme activities [26, 28]. Negative control
reactions were performed in the absence of substrate [6].
The media were freshly prepared just before incubation and
nitro BT was added after being dissolved in a heated
mixture of dimethylformamide and ethanol (ﬁnal dilution
of each solvent in the medium was 2% v/v). For the
demonstration of both NAD
?- and NADP
?-dependent IDH
activity, sections were incubated for 45 min at 37C. For
activity of G6PDH, 6PGDH, MDH and H6PDH sections
were incubated for 30, 10, 45, and 45 min, respectively at
37C. Sections were then rinsed with hot phosphate buffer
(0.1 M, pH 5.3, 65C) to remove the incubation medium
and to immediately stop the reaction. Afterwards, sections
were embedded in glycerol jelly.
Image analysis
The ﬁnal reaction product of dehydrogenase activity (nitro
BT-formazan) was analyzed with the use of quantitative
image analysis, using a Vanox-T photomicroscope with a
109 objective (Olympus, Tokyo, Japan) and a CFW-
1312M 1,360 9 1,024 pixel 10-bit monochrome FireWire
camera (Scion, Tucson, AZ) mounted on the front port of
the Vanox using adapting optics. Sections were illuminated
with white light that was ﬁltered by a monochromatic ﬁlter
of 585 nm and an infrared blocking ﬁlter [7] to correctly
measure the absorbance of both mono- and di-formazans
[26, 29]. Absorbance calibration of the images was per-
formed with the use of a calibrated 10-step density tablet
(Stouffer, South Bend, IN). After measuring the step tablet,
known absorbance values were related to measured grey
values using the built-in calibration function of ImageJ,
using the Rodbard function. Density calibrated images were
recorded in one single run and stored on disk for analysis.
The resolution used prevented distributional errors [7]. All
settings were maintained throughout the recording session
and at the end of the session veriﬁed against the step tablet
values. Software used for capturing was swf-image, a Scion
proprietary camera driver, as an extension to the image
Table 1 Baseline
characteristics of 98
glioblastoma patients included
in survival analysis
Data are mean (range) or
number (%)
KPS Karnofsky performance
score, IDH1 isocitrate
dehydrogenase 1, wt non-
mutated
IDH1 wt IDH1 mutated P value
Samples 80 18
Tumor occurrence Primary glioblastoma 75 (95%) 10 (56%) \0.001
Secondary glioblastoma 5 (5%) 8 (44%)
Age (years) 58 (27–80) 41 (28–62) \0.001
Gender M 44 (55%) 9 (50%) 0.704
F 36 (45%) 9 (50%)
KPS 75 (50–90) 76 (50–90) 0.813
Surgical procedure Biopsy or radical resection 34 (43%) 7 (39%) 0.782
Gross total removal 46 (57%) 11(61%)
Irradiation dosage (Gy) 39 (0–78) 48 (0–66) 0.193
Other therapy No additional therapy 53 (66%) 8 (44%) 0.086
Additional therapy 27 (34%) 10 (56%)
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123processing application ImageJ, developed by Wayne Ras-
band [23]. ObjectJ, a plugin for non-destructive image
marking and result linking developed by Norbert Vischer
and Stelian Nastase at the Department of Biology of the
University of Amsterdam [31], was used to indicate regions
of interest (ROI) that were measured. Using the ObjectJ
plugin, mean absorbance values within the ROI were col-
lected from the test reaction and the control reaction,
allowing calculation of speciﬁc activity of IDHs, G6PDH,
6PGDH, MDH and H6PDH, respectively [29]. Activity was
expressed as micromoles NADPH produced per milliliter of
tissue/min. The use of ObjectJ allows a retrospective quality
control study of areas measured.
Statistical analysis
Statistical processing of data was performed using Excel
2002 (Microsoft, San Jose, CA) and SPSS 16.02 for
Windows (SPSS, Chicago, IL). Associations between the
different dehydrogenase activities and IDH1 mutations
were assessed by t test. The association between IDH1
mutations or NADP
?-dependent IDH activity and survival
time was tested with Cox proportional hazard models. After
the individual tests, factors with P values less than 0.10
were included in the multivariable Cox model to determine
the factors associated with survival time (Table 2).
Results
Mutational proﬁling of IDH1 and IDH2 in glioblastoma
A panel of 109 glioblastoma (94 primary and 15 second-
ary) for which the prevalence of IDH1
R132 mutations had
already been assessed [5] was also analyzed for IDH2
mutations. No somatic IDH2 mutations were observed in
this set of tumors.
Mutation at IDH1
R132 is an independent prognostic
factor for improved survival in glioblastoma patients
In a subset of 98 glioblastoma with known follow-up, the
overall survival of both primary and secondary glioblas-
toma was increased for patients whose tumors carried an
IDH1 mutation (P = 0.002, log rank test). Moreover,
patients without mutation were on average 58 years old,
whereas patients with mutation were 41 years old. When
corrected for age, Karnofsky performance status (KPS),
extent of surgery, received dosage of radiotherapy, addi-
tional chemotherapy or treatment other than radiotherapy
(Table 2), the mutational status of IDH1
R132 was a strong
independent prognostic factor for improved overall
survival (P\0.001; Fig. 1; Table 2). This signiﬁcant
association indicates that the presence of IDH1 mutation
correlates with an improved prognosis for glioblastoma
patients which is in agreement with other studies [19, 24,
25, 34].
IDH1
R132 mutations are associated with diminished
in situ NADP
?-dependent IDH activity in glioblastoma
cells
Activity of NADP
?-dependent IDH was determined in
glioblastoma cryostat sections of tumor samples of 51
glioblastoma patients (Fig. 2) to evaluate whether and to
what extent IDH1 mutations affect the metabolic status of
glioblastoma cells. These 51 tumor samples included 15
tumor samples mutated at IDH1
R132, of these, 12 contained
the R132H mutation, two the R132C mutation and one
sample the R132G mutation (Fig. 3b). Activity was het-
erogeneous within tumor samples (Fig. 2c). As this could
be associated with the presence of necrosis, the regions
analyzed were ‘validated’ by H&E staining of adjacent
sections to contain vital tumor tissue (Fig. 2b, d). Repre-
sentative areas with the most uniform activity of each
Table 2 Univariate and multivariable association between 98 glioblastoma patient characteristics and overall survival
Univariate Cox regression Multivariate Cox regression
HR 95% CI P HR 95% CI P
Age (per year) 1.028 1.012–1.045 0.001 1.010 0.990–1.031 0.328
Sex 1.114 0.728–1.799 0.559 * * *
KPS (per 10 points) 0.969 0.949–0.989 0.002 0.974 0.954–0.995 0.018
Resection (gross total removal vs. biopsy or resection) 0.628 0.402–0.980 0.040 0.807 0.508–1.282 0.364
Irradiation dosage, per Gy 0.979 0.970–0.987 \0.001 0.979 0.968–0.990 \0.001
Other therapy (additional therapy vs. non-additional therapy) 0.415 0.261–0.660 \0.001 0.605 0.336–1.092 0.095
Secondary versus primary glioblastoma 0.598 0.305–1.172 0.134 * * *
IDH1 mutated versus non-mutated 0.273 1.137–0.543 \0.001 0.209 0.093–0.471 \0.001
KPS Karnofsky performance score, IDH1 isocitrate dehydrogenase 1, HR hazard ratio, CI conﬁdence interval
* Not included in multivariate analysis
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123section were selected to measure the enzyme activity. Of
note, no activity was observed in regions of necrosis.
Next, we correlated the mutational status of IDH1
with the quantitative data of NADP
?-dependent IDH
activity (Fig. 3a). The presence of IDH1 mutations was
inversely associated with NADP
?-dependent IDH activity
(P = 0.001). The individual NADP
?-dependent IDH
activity values are shown in Fig. 3b. Activity varied
strongly among tumors; nevertheless, we observed a two-
fold reduction in activity.
As a control, the activity of NADP
?-dependent G6PDH
and NAD
?-dependent IDH was assessed on serial sections
of the same samples. IDH1 mutations were not associated
with NADP
?-dependent G6PDH activity (P = 0.60;
Fig. 3c)orwithNAD
?-dependentIDHactivity(P = 0.639;
Fig. 3d),indicatingthatthecorrelationwithIDH1mutations
is speciﬁc for the NADP
?-dependent IDH activity.
Table 3 shows that IDH had the largest capacity to
generate NADPH in normal brain, wild-type glioblastoma
and IDH1-mutated glioblastoma. Sixty-ﬁve % of the
NADPH-producing capacity was provided by IDH. The
total NADPH-generating capacity was signiﬁcantly reduced
by 38% by the IDH1
R132 mutation (P = 0.02; Table 3).
For this experiment, a subset of 13 wild-type tumor sam-
ples, 13 tumor samples mutated at IDH1
R132 and 5 samples
of normal brain were used. Again, the difference between
NADP
?-dependent IDH activity in non-mutated and
mutated tumor samples was signiﬁcant (P = 0.01).
The combination of our ﬁndings indicates that IDH1
mutations are associated with improved survival in glio-
blastoma and that IDH1 mutated glioblastoma samples
have a lower NADPH-producing capacity, thus suggesting
Fig. 1 Adjusted survival curves comparing IDH1
R132 mutated and
non-mutated glioblastoma patients. Constructed with the use of multi-
variable Cox proportional hazards regression, and adjusted for age,
Karnofsky performance score, irradiation and additional treatments
Fig. 2 NADP
?-dependent IDH
activity in IDH1
R132 non-
mutated (n = 36) and mutated
(n = 15) tumors. NADP
?-
dependent IDH activity staining
of IDH1
R132 non-mutated a and
mutated c glioblastoma cryostat
sections. The amount of blue
color (nitro BT-formazan)
directly reﬂects NADP
?-
dependent IDH activity
(production of NADPH). H&E
staining of serial sections of
non-mutated (b) and mutated
(d) samples
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123that diminished NADPH formation correlates with
improved survival. In 43 glioblastoma patients, lower
NADP
?-dependent IDH activity appeared to be correlated
with improved survival. However, the correlation was not
signiﬁcant (hazard ratio: 1.108 lmoles NADPH produced/
ml of tissue/min; CI 0.880–1.394; P = 0.38), probably due
to the limited size of the examined cohort.
Discussion
A high percentage of human gliomas has been found to
harbour mutations in the metabolic enzyme IDH1.
We conﬁrm here the previously reported ﬁndings that
IDH1 mutations are predominantly found in secondary
glioblastoma and in younger patients (Table 1)[ 5, 10, 19,
24, 25, 32, 34] and that IDH1 mutations correlate inde-
pendently with improved prognosis in glioblastoma
patients (Table 2; Fig. 1).
When IDH1 and IDH2 mutations are ectopically
(over)expressed in human cells, they reduce NADP
?-
dependent IDH activity [12, 36]. Thus far, nothing was
known about the effect of IDH1 and IDH2 mutations on
IDH activity in glioblastoma in situ. In order to shed light
on the functional effects of IDH1 mutations, we exploited
an integrated approach to measure NADP
?-dependent IDH
activity in situ on brain tumor samples. Using this strategy,
we showed for the ﬁrst time that IDH1
R132 mutations are
a b
c d 4
3
2
1
0
4
6
4
2
0
6
4
2
0
3
2
1
0
Fig. 3 Capacity (maximum
velocity; Vmax)o f
dehydrogenases in IDH
R132
non-mutated and mutated
tumors expressed as micromoles
NADPH or NADH produced/ml
of tissue/min, ±SD. NADP
?-
dependent IDH activity (a);
individual values of NADP
?-
dependent IDH activity (b);
NADP
?-dependent G6PD
activity (c); NAD
?-dependent
IDH activity (d)
Table 3 Capacity (maximum velocity; Vmax) of NADPH-generating
dehydrogenases as determined by image analysis in cryostat sections
of non-cancerous brain (n = 5), wild-type glioblastoma (n = 13) and
IDH-mutated glioblastoma (n = 13) and expressed as mean micro-
moles NADPH generated per milliliters of tissue per min ± SD
[7, 28, 29]
Normal brain Wild-type glioblastoma IDH1-mutated glioblastoma
IDH 1.95 ± 1.17 3.82 ± 2.03 2.02 ± 1.73
G6PDH 0.99 ± 0.16 1.59 ± 0.76 1.12 ± 0.74
6PGDH 0.10 ± 0.05 0.23 ± 0.16 0.20 ± 0.10
MDH 0.30 ± 0.12 0.19 ± 0.17 0.23 ± 0.20
H6PDH 0.02 ± 0.01 0.09 ± 0.05 0.04 ± 0.02
Total capacity 3.34 ± 1.12 5.88 ± 2.73 3.65 ± 2.29
IDH isocitrate dehydrogenase, G6PDH glucose-6-phosphate dehydrogenase, 6PGDH 6-phosphogluconate dehydrogenase, MDH malate dehy-
drogenase, H6PDH hexose-6-phosphate dehydrogenase
492 Acta Neuropathol (2010) 119:487–494
123associated with on average a twofold decreased NADP
?-
dependent IDH activity in the tumors. As both IDH1 and
IDH2 use NADP
? as a co-factor, we cannot differentiate
between the activity of IDH1 and IDH2. However, con-
sidering that we did not observe any IDH2 somatic
mutations in the samples that we analyzed, our work
indicates that the reduced NADP
?-dependent IDH activity
is associated with the presence of IDH1 mutations. The loss
of NADPH production capacity by mutated IDH1 is con-
siderable (38%) because NADP-dependent IDH activity
represents 65% of the total capacity (Table 3). As mutated
IDH1 consumes rather than produces NADPH [8], the loss
of NADPH for scavenging oxygen radicals and detoxiﬁ-
cation is likely even more profound. It may explain
prolonged survival of glioblastoma patients with the IDH1
mutation. NADPH is necessary for biosynthetic processes
such as lipogenesis and for detoxiﬁcation [14]. Low levels
of cytoplasmic NADPH result in impaired reduction of
glutathione (GSH), which is a major scavenger of oxygen
radicals in the cells. Diminished levels of GSH thus lead to
oxidative stress that can ultimately cause DNA damage and
induce apoptosis [13, 16]. Oxidative stress is generally
increased by irradiation and chemotherapy [20], and we
speculate that it is further enhanced in the presence of
IDH1 mutations. Thus, tumors with the mutation may be
less resistant to irradiation and chemotherapy which
explains the prolonged survival of patients with mutated
tumors. Low levels of cytoplasmic NADPH also affect the
thioredoxin system, a family of small redox active proteins
that are kept in reduced form by the NADPH-dependent
thioredoxin reductase and help to maintain the redox state
in cells [4]. Thioredoxins are frequently overexpressed in
cancer and play a role in resistance to irradiation and
chemotherapy like reduced GSH.
In conclusion, we have shown that IDH1
R132 mutations
correlate with diminished NADPH production in situ in
glioblastoma and provide an independent survival advan-
tage to glioblastoma patients. This may be explained by a
reduced capacity to produce NADPH in combination with
NADPH consumption by mutated IDH1 instead of NADPH
production by wild-type IDH1. Our data suggest that
NADPH metabolism may be therapeutically exploited in
gliomas.
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